As the chart shows, the stock price benefited from three large jumps in June, August, and December. Here's how it went down. In June, at the annual American Society of Clinical Oncology (ASCO) meeting ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T ...

Shares of Bluebird Bio BLUE were up nearly 20% in early morning trading Monday as investors responded to the company's announcement that its CAR-T candidate, bb2121, produced encouraging results in ...

Every year, the Mystery Writers of America celebrates the best in mystery fiction, non-fiction, and television published or produced at the annual Edgar Awards. At this year's 72nd Gala Banquet, held ...

Clinical-stage gene therapy specialist bluebird bio (NASDAQ: BLUE) reported second-quarter earnings last week, which mostly just served as a reminder of its pipeline progress because revenue and ...

bluebird bio (NASDAQ: BLUE) reported fourth-quarter earnings after the closing bell on Wednesday. Without any products on the market, the quarterly pipeline update is more important than the revenue ...

DURHAM – Potential therapies for several rare diseases and cancers will be manufactured in Durham, according to Cambridge, Mass.-based bluebird bio, which has purchased a 125,000-square foot ...

It was a heck of a year for bluebird bio (NASDAQ: BLUE), with shares more than tripling in 2017, although they pulled back a little in December; the biotech ended the year up only 188.7%. As the chart ...